Mithrl has raised $20 million in a Series A round led by Obvious Ventures to expand deployment of its “biomedical world model” across biopharma R&D. The company says its platform helps teams move from idea to IND faster by combining curated validated biology with agentic AI for model routing, token optimization, and content orchestration. Mithrl’s financing is intended to support second-generation platform development and an early access program scheduled to launch Sept. 21. The company claims its approach reduces compute needs by enabling agents to reason over validated biology rather than searching broadly across less constrained information sources. If adoption broadens, the funding signals increased investor confidence in agentic AI workflows that are designed to integrate into existing drug discovery environments while maintaining source-aware outputs intended for hypothesis generation.